

# The immunoproteasome in antigen processing and other immunological functions

Michael Basler<sup>1,2</sup>, Christopher J Kirk<sup>3</sup> and Marcus Groettrup<sup>1,2</sup>

Treatment of cells with interferon- $\gamma$  leads to the replacement of the constitutive catalytic proteasome subunits  $\beta 1$ ,  $\beta 2$ , and  $\beta 5$  by the inducible subunits LMP2 ( $\beta 1i$ ), MECL-1 ( $\beta 2i$ ), and LMP7 ( $\beta 5i$ ), respectively, building the so-called immunoproteasome. The incorporation of these subunits is required for the production of numerous MHC class-I restricted T cell epitopes. Recently, new evidence for an involvement of the immunoproteasome in other facets of the immune response emerged. Investigations of autoimmune diseases in animal models and a genetic predisposition of  $\beta 5i$  in human autoimmune disorders suggest a crucial function of the immunoproteasome in proinflammatory diseases. The recent elucidation of the high-resolution structure of the immunoproteasome will facilitate the design of immunoproteasome selective inhibitors for pharmacological intervention.

## Addresses

<sup>1</sup> Division of Immunology, Department of Biology, University of Konstanz, Universitätsstrasse 10, D-78457 Konstanz, Germany

<sup>2</sup> Biotechnology Institute Thurgau (BITg) at the University of Konstanz, CH-8280 Kreuzlingen, Switzerland

<sup>3</sup> Onyx Pharmaceuticals, South San Francisco, CA 94080, USA

## Introduction

The 20S proteasome is a large intracellular multicatalytic protease consisting of  $\alpha$  and  $\beta$  subunits that build a barrel-shaped complex of four rings with seven subunits each [1,2<sup>••</sup>]. In cells of hematopoietic origin, or during an immune response in the context of interferon- $\gamma$  (IFN- $\gamma$ ) or tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) stimulation, the three catalytically active  $\beta$  subunits ( $\beta 1$ ,  $\beta 2$ , and  $\beta 5$ ) are replaced by the inducible catalytic subunits LMP2 ( $\beta 1i$ ), MECL-1 ( $\beta 2i$ ), and LMP7 ( $\beta 5i$ ) during proteasome neosynthesis. The immunological benefit of the resulting ‘immunoproteasome’ is attributed to structural changes in substrate binding pockets [2<sup>••</sup>] and an altered cleavage pattern of the multicatalytic complex, thus optimizing quality and

quantity of the generated peptides for presentation on MHC class I molecules [3–6]. Because of a pivotal role in class-I ligand generation, the immunoproteasome shapes the naïve CD8-T-cell repertoire in the thymus and cytotoxic T-cell responses in the periphery [7,8,9<sup>•</sup>,10–12]. Recently, novel functions of immunoproteasomes in autoimmune diseases, virus induced neuroinflammation, T cell expansion, T helper cell differentiation, and cytokine production have been proposed [13<sup>••</sup>,14–16]. In this review we discuss the latest findings on the immunoproteasome in antigen processing as well as these novel functions.

## The immunoproteasome in antigen processing

The major histocompatibility complex (MHC) class-I restricted pathway of antigen processing allows the presentation of intracellular antigens to cytotoxic T lymphocytes. The main protease involved in this process is the proteasome [17–19]. It is generally assumed that the immunoproteasome improves quality and quantity of generated class-I ligands. Indeed, a proteomic analysis of MHC-I associated peptides derived from wild type (WT) and  $\beta 2i^{-/-}/\beta 5i^{-/-}$ -double deficient mouse dendritic cells (DC) demonstrated that immunoproteasomes dramatically increase the abundance and diversity of class-I ligands [20]. The recently solved crystal structures of the constitutive proteasome and immunoproteasome of the mouse at 2.9 Å provides an explanation for enhanced antigen processing by immunoproteasomes [2<sup>••</sup>] (Table 1). The  $\beta 1i$  substrate-binding channel is lined with hydrophobic amino acids, which enhances the production of MHC-I epitopes ending with small, nonpolar residues. The  $\beta 5i$ -mediated peptide bond hydrolysis might be kinetically favored by an increased hydrophilicity of the active site and additional hydrogen bonds shaping the oxyanion hole. From a structural point of view, the exchange of  $\beta 2/\beta 2i$  is not obvious, and it is quite an enigma why, nevertheless,  $\beta 2i$  deficient mice are protected from experimental colitis [14] and why  $\beta 2i$  influences homeostatic proliferation [21].

Analysis of the T cell response in murine cytomegalovirus (MCMV) infected  $\beta 5i$ -deficient mice revealed a critical role for immunoproteasomes [22]. Interestingly, all MCMV-derived CD8<sup>+</sup> T cell epitopes tested were affected by the loss of  $\beta 5i$ , suggesting that the virus has evolved a primary sequence poorly processed by constitutive proteasomes. The authors hypothesized that DCs containing both immunoproteasomes and constitutive proteasomes elicit the acute MCMV-specific T cell response, whereas the chronic MCMV infection is maintained in cells expressing constitutive proteasomes.

Table 1

## Immunoproteasome subunit-induced alterations in the 20S proteasome (information derived from Ref. [2\*\*])

Immunoproteasome	Alteration – immuno vs. constitutive subunit	Alteration in substrate binding channel	Consequences
MECL-1 ( $\beta 2i$ )	D53E	Identical substrate binding channel.	The rationale for the incorporation of subunit $\beta 2i$ into the immunoproteasome remains elusive.
LMP2 ( $\beta 1i$ )	T20V, T31F, R45L, and T52A	Increase in hydrophobicity of S1 pocket. Diminishes S1 pocket in size.	CD8 <sup>+</sup> T cell epitopes with non-polar C-termini such as Ile, Leu, or Val are produced. These epitopes are better suited for presentation on MHC-I molecules. Peptide bond hydrolysis preferentially occurs after small, hydrophobic, and branched residues. Altered amino acid preference at P3.
LMP7 ( $\beta 5i$ )	T22A, and A27V in LMP2; Y114H in $\beta 2i$ Ala20, Met45, Ala49, and Cys52 in S1 pocket are unchanged. Gly48 Ser or Cys Ala27Ser Distinct conformation of Met45 A46S, V127T SerO $\gamma$ , Thr127O $\gamma$ , and Gly47NH	Decrease size and increase polarity of S3 pocket. Hydrophobic character of S1 pocket is maintained. Shallow S2 pocket. Restricts size of S3 pocket and endows it with a more hydrophilic character. Results in spacious S1 pocket in $\beta 5i$ . Increase the hydrophilicity surrounding the active site nucleophilic Thr1O $\gamma$ of $\beta 5i$ . Build unique hydrogen network.	Both $\beta 5$ and $\beta 5i$ are responsible for the chymotrypsin-like activity of the proteasome. Limits size of P2 amino acids. Limits P3 amino acids to small hydrophilic amino acids. $\beta 5i$ can accommodate larger amino acids in S1 compared to $\beta 5$ . Elevated polarity might favor peptide bond hydrolysis. Stabilization of the tetrahedral transition state during catalysis.

Hence, with the help of expression of immunoproteasome-dependent epitopes, MCMV may evade immune recognition leading to viral persistence.


The structural properties rather than the proteolytic activity of immunoproteasome subunits are needed for the generation of some epitopes [23,24], but the underlying mechanisms have remained elusive. In a recent study, the presentation of the male HY Ag-derived epitope UTY<sub>246–254</sub> and the influenza virus matrix M1 58–66 epitope were analyzed, which both were dependent on the structure of  $\beta 1i$  or  $\beta 5i$ , respectively, but not on their catalytic activity [25\*]. With different proteasome inhibitors it was shown that  $\beta 5i$  protects matrix M1 58–66 from cleavage by  $\beta 5$  and  $\beta 1i$  protects UTY<sub>246–254</sub> from cleavage by  $\beta 1$ , proposing a novel mechanistic basis for the function of immunoproteasome subunits (Figure 1).

Using newly developed immunoproteasome subunit-specific antibodies, Guillaume *et al.* isolated and characterized human 20S proteasomes that are intermediate between the standard and the immunoproteasome [26\*\*]. Rather than jointly incorporating  $\beta 1i$ ,  $\beta 2i$ , and  $\beta 5i$  into immunoproteasomes, intermediate proteasomes incorporate only one ( $\beta 5i$ ) or two ( $\beta 2i$  and  $\beta 5i$ ) immunoproteasome subunits. The existence of intermediate proteasomes is consistent with the rules of cooperative assembly of immunoproteasome subunits [27–29]. Depending on the investigated organ, the intermediate

proteasomes represent between 30% and 50% of the total proteasome content. Not unexpectedly, the intermediate proteasomes have different cleavage properties in the generation of class I peptides [26\*\*,30]. The existence of 4 different types of proteasomes within cells broadens the MHC-I-presented peptidome. It is conceivable that an asymmetric hybrid proteasome, consisting of immunoproteasome and constitutive proteasome, exists. Nevertheless, Guillaume *et al.* did not find asymmetrical  $\beta 5/\beta 5i$  proteasomes in melanoma cells and kidney samples [26\*\*].

Mice deficient for one or two immunoproteasome catalytic subunits have relatively modest changes in antigen presentation (summarized in [10]). To investigate the antiviral immune response in mice devoid of immunoproteasome activity, we analyzed the lymphocytic choriomeningitis virus specific T cell response in  $\beta 1i^{-/-}/\beta 2i^{-/-}$  double-deficient mice treated with the  $\beta 5i$ -selective inhibitor ONX0914 to generate mice devoid of immunoproteasome activity [11]. Mice devoid of immunoproteasome activity could mount a strong CTL-response, although the T cell response to some epitopes was slightly altered compared to WT mice. Interestingly,  $\beta 1i$  and  $\beta 2i$  are needed for the generation of the lymphocytic choriomeningitis virus (LCMV)-derived epitope NP<sub>205–212</sub>, whereas  $\beta 5i$  destroys NP<sub>205–212</sub> in  $\beta 1i/\beta 2i$  deficient cells. A more pronounced phenotype with respect to antigen presentation was observed in genetically engineered mice completely lacking immunoproteasome subunits [31\*\*]. Similar to

Figure 1



The immunoproteasome protects a CD8<sup>+</sup> T cell epitope. A protein containing a CD8<sup>+</sup> T cell epitope (in red) is destroyed by the constitutive proteasome. The induction of the immunoproteasome subunits and the replacement of their corresponding constitutive subunits protects this T cell epitope from the destruction by the constitutive proteasome and the peptide can be presented to cytotoxic T cells (T<sub>CD8+</sub>) [25\*].

$\beta 5i$ -deficient mice [32], MHC-I surface expression in triply deficient mice was reduced by approx. 50%. Presentation of numerous CD8<sup>+</sup> T cell epitopes derived from different antigens was markedly changed in triple-deficient mice. Interestingly, most investigated epitopes were poorly presented in cells completely lacking immunoproteasome subunits, except for the LCMV-derived epitope GP<sub>276–286</sub>, which elicited a significantly increased CTL-response in LCMV-infected triple-deficient mice. An increased presentation of this T cell epitope was already previously observed in  $\beta 1i$  and  $\beta 5i$  single-deficient mice [7,33], whereas  $\beta 2i$ -deficient mice demonstrated an increased GP<sub>276–286</sub>-CTL-response owing to alterations in the T cell repertoire [8]. Mass spectrometric analysis of MHC-I bound peptides on splenocytes derived from  $\beta 1i/\beta 2i/\beta 5i$  triple-deficient or WT mice revealed marked changes in the MHC-I peptide repertoire [31\*\*]. Approx. 1/3 of the detected peptides were uniquely presented on WT cells,

1/3 uniquely on triple-deficient cells, and 1/3 was presented on both cell types. Interestingly, triple-deficient mice rejected adoptively transferred WT splenocytes, whereas adoptively transferred immunoproteasome-deficient cells were tolerated in WT mice. A similar observation was made with WT skin grafted onto  $\beta 5i^{-/-}$  mice, but not vice versa [4]. Why the immunoproteasome-deficient transplants are not rejected from WT mice, although they present approx. 1/3 unique MHC-I peptides, has remained elusive and needs further investigation.

#### Other immunological functions of the immunoproteasome


In recent years it became apparent that immunoproteasomes do not only function to change the processing of MHC-I ligands, but also possess additional immunological functions. An involvement of the immunoproteasome in NF- $\kappa$ B activation has remained controversial [34–37].

Using  $\beta$ 1i and  $\beta$ 5i specific inhibitors, Jang *et al.* recently demonstrated that immunoproteasomes are not essential for canonical NF- $\kappa$ B activation [38]. In 2001, Chen *et al.* reported that immunoproteasomes are major determinants of the hierarchy of T cell epitopes during antiviral CTL responses. Already in this study it was noted that adoptively transferred  $\beta$ 1i-deficient T cells were not able to expand in influenza virus infected WT hosts [9<sup>\*</sup>], but this phenomenon was suspected to rely on the rejection of the adoptively transferred cells [39]. The inability of immunoproteasome subunit-deficient T cells to expand in a virus infected WT host was also observed by Moebius *et al.*, who provided strong evidence that the loss of  $\beta$ 5i-deficient T cells after transfer was not a consequence of graft rejection by the host [15]. Hence, the immunoproteasome possesses a so far uncharacterized function in controlling T cell expansion in an infected host and therefore might qualify as a potential new target for the suppression of undesired pro-inflammatory T cell responses. Indeed, with the help of a  $\beta$ 5i-selective inhibitor (named PR-957 and later renamed to ONX 0914), the autoreactive immune responses in two mouse models of arthritis and a model of diabetes could be suppressed [13<sup>\*\*</sup>]. Additionally, a new function of immunoproteasomes in cytokine production and T helper cell differentiation was proposed [13<sup>\*\*</sup>]. Furthermore,  $\beta$ 5i inhibition prevented experimental colitis [14], murine lupus like disease [40], and Hashimoto's thyroiditis [41]. Not merely inhibition, but also genetic deficiency of immunoproteasome subunits attenuates inflammatory bowel disease in mouse models, suggesting a special contribution of the immunoproteasome in the etiology of inflammatory bowel diseases [14,42,43]. Disparate results have been obtained in mouse models of murine autoimmune encephalomyelitis (EAE). Frausto *et al.* demonstrated that the immunoproteasome is not required for the establishment of myelin oligodendrocyte glycoprotein-induced EAE in  $\beta$ 1i-deficient mice [44], whereas Seifert *et al.* reported an exacerbation of EAE symptoms in  $\beta$ 5i<sup>-/-</sup> mice [45<sup>\*</sup>]. Additionally, it was demonstrated that immunoproteasomes are required for the efficient degradation of poly-ubiquitylated proteins and the preservation of cell viability under cytokine-induced oxidative stress [45<sup>\*</sup>,46]. However, how an immunoproteasome subunit should control substrate access to the 26S proteasomes has remained elusive especially because the high-resolution crystal structures of the 20S constitutive – and immunoproteasome of the mouse did not reveal any difference in the  $\alpha$ -rings where proteasome regulators bind [2<sup>\*\*</sup>].

Several recent human genetics studies support the involvement of immunoproteasomes in inflammatory disorders [47,48<sup>\*</sup>,49<sup>\*</sup>]. Genetic mapping of patients with an autosomal-recessive auto-inflammatory syndrome characterized by joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome (JMP syndrome) revealed a point mutation (T75M) in

PSMB8, the gene encoding for  $\beta$ 5i, leading to a disruption of the tertiary structure of  $\beta$ 5i [47]. Patients bearing a G176V mutation in the PSMB8 gene, suffered from a newly recognized type of Japanese autoinflammatory syndrome with lipodystrophy (JASL). The mutation manifested in low  $\beta$ 5i expression causing increased p38 phosphorylation, which resulted in increased IL-6 production [48<sup>\*</sup>]. Similarly, Arima *et al.* found that a G201V mutation in the PSMB8 gene causes the autoinflammatory disorder Nakajo-Nishimura syndrome [49<sup>\*</sup>]. The mutation disrupts the  $\beta$ -sheet structure of  $\beta$ 5i, resulting in accumulation of poly-ubiquitylated and oxidized proteins within cells expressing immunoproteasomes. Furthermore, a strong association between human type 1 diabetes and two single nucleotide polymorphisms in the PSMB8 gene demonstrated a correlation of autoimmune diseases with genetic alteration of  $\beta$ 5i [50<sup>\*</sup>]. The authors also showed that  $\beta$ 2i/ $\beta$ 5i double-deficient mice develop CD8<sup>+</sup> T cell-mediated early-stage multiorgan autoimmunity following irradiation and bone marrow reconstitution, suggesting that immunosubunits also play an important function in the prevention of CD8<sup>+</sup> T cell-mediated autoimmune reactions [50<sup>\*</sup>] as has been hypothesized previously [51].

Figure 2



Influence of LMP7 on T helper cell differentiation. Depending on the cytokine environment naïve T helper cells (Th0) differentiate into Th1, Th2, Th17, or regulatory T cells (Treg). †: enhanced differentiation; →: no influence; ‡: reduced differentiation [52<sup>\*</sup>].

How does the immunoproteasome exert its effect in autoimmune diseases? A likely explanation could be through the regulation of inflammatory cytokines or T helper cell differentiation. Indeed, selective inhibition or genetic ablation of  $\beta 5i$  resulted in diminished Th1 and Th17 differentiation, enhanced development of regulatory T cells, but no effect on Th2 differentiation [13<sup>\*\*</sup>,43,52<sup>\*</sup>] (Figure 2). Muchamuel *et al.* first demonstrated that selective inhibition of  $\beta 5i$  blocked the production of IL-23 by activated monocytes and the production of IFN- $\gamma$  and IL-2 by T cells, whereas the inhibition of  $\beta 5$  did not substantially affect cytokine release [13<sup>\*\*</sup>]. Mixed proteasomes expressed in  $\beta 1i^{-/-}$  mice decrease cytokine production by DCs, which supports the notion of immunoproteasomes playing a role in cytokine production [53]. PMA/ionomycin stimulation of  $\beta 2i^{-/-}/\beta 5i^{-/-}$  derived splenocytes demonstrated that immunoproteasomes regulate the expression of IFN- $\gamma$ , IL-4, IL-10, IL-2R $\beta$ , GATA3, and T-bet [54]. Furthermore, LPS-stimulated thioglycollate-elicited macrophages from immunoproteasome-deficient mice were found to produce markedly reduced NO levels owing to defects in the TRIF/TRAM and IRF-3 pathway [55].

## Conclusions

The severe phenotype in MHC-I ligand generation of triply immunoproteasome-deficient mice [31<sup>\*\*</sup>] and the existence of intermediate immunoproteasomes diversifying the MHC-I repertoire [26<sup>\*\*</sup>] emphasize the important role of the immunoproteasome in antigen processing. The development of a specific inhibitor of  $\beta 5i$  has revealed a new function of immunoproteasomes in inflammatory autoimmune disorders. However, how the immunoproteasome is mechanistically involved in the newly described processes has remained unclear so far. We propose that the immunoproteasome might selectively processes a factor that is required for regulating cytokine production and T helper cell differentiation, but such a factor remains to be identified. Though selective inhibitors have been described, the recently solved immunoproteasome crystal structures will promote the structure-guided design of new inhibitory lead structures [2<sup>\*\*</sup>]. Finally, clinical investigations, with either ONX 0914 or other immunoproteasome inhibitors will show whether the promising pre-clinical findings can be translated to human medicine.

## Conflict of interest

C.J.K. is an employee of and shareholder in Onyx Pharmaceuticals. M.B. and M.G. have no financial conflicts of interest.

## Acknowledgements

This work was funded by the German Research Foundation grant GR1517/12-1, the Konstanz Research School Chemical Biology, the Fritz Thyssen Foundation grant AZ 10.10.2.122, and the Swiss National Science Foundation grant 31003A\_138451.

## References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Kloetzel PM: **Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII.** *Nat Immunol* 2004, **5**:661-669.
2. Huber EM, Basler M, Schwab R, Heinemeyer W, Kirk CJ, Groettrup M, Groll M: **Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity.** *Cell* 2012, **148**:727-738.
- Describes the high-resolution crystal structure of the mouse immunoproteasome and constitutive proteasome.
3. Groettrup M, Ruppert T, Kuehn L, Seeger M, Standera S, Koszinowski U, Kloetzel PM: **The interferon- $\gamma$ -inducible 11S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20S proteasome in vitro.** *J Biol Chem* 1995, **270**:23808-23815.
4. Toes REM, Nussbaum AK, Degermann S, Schirle M, Emmerich NPN, Kraft M, Laplace C, Zwinderman A, Dick TP, Muller J *et al.*: **Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products.** *J Exp Med* 2001, **194**:1-12.
5. Schwarz K, van den Broek M, Kostka S, Kraft R, Soza A, Schmidtke G, Kloetzel PM, Groettrup M: **Overexpression of the proteasome subunits LMP2 LMP7, and MECL-1 but not PA28 $\alpha$ / $\beta$  enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope.** *J Immunol* 2000, **165**:768-778.
6. Sijts AJAM, Standera S, Toes REM, Ruppert T, Beekman NJCM, vanVeelen PA, Ossendorp FA, Melief CJM, Kloetzel PM: **MHC class I antigen processing of an Adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells.** *J Immunol* 2000, **164**:4500-4506.
7. Basler M, Youhnovski N, Van Den Broek M, Przybylski M, Groettrup M: **Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus.** *J Immunol* 2004, **173**:3925-3934.
8. Basler M, Moebius J, Elenich L, Groettrup M, Monaco JJ: **An altered T cell repertoire in MECL-1-deficient mice.** *J Immunol* 2006, **176**:6665-6672.
9. Chen WS, Norbury CC, Cho YJ, Yewdell JW, Bennink JR: **Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens.** *J Exp Med* 2001, **193**:1319-1326.
- Describes that immunoproteasomes alter the T cell repertoire and shape the epitope hierarchy of the antiviral cytotoxic T lymphocyte response.
10. Groettrup M, Kirk CJ, Basler M: **Proteasomes in immune cells: more than peptide producers?** *Nat Rev Immunol* 2010, **10**:73-78.
11. Basler M, Beck U, Kirk CJ, Groettrup M: **The antiviral immune response in mice devoid of immunoproteasome activity.** *J Immunol* 2011, **187**:5548-5557.
12. Osterloh P, Linkemann K, Tenzer S, Rammensee HG, Radsak MP, Busch DH, Schild H: **Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses.** *Proc Natl Acad Sci USA* 2006, **103**:5042-5047.
13. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J *et al.*: **A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.** *Nat Med* 2009, **15**:781-787.
- The paper describes that immunoproteasomes are involved in cytokine production, Th17 cell differentiation, and autoimmune diseases.
14. Basler M, Dajee M, Moll C, Groettrup M, Kirk CJ: **Prevention of experimental colitis by a selective inhibitor of the immunoproteasome.** *J Immunol* 2010, **185**:634-641.

15. Moebius J, van den Broek M, Groettrup M, Basler M: **Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice.** *Eur J Immunol* 2010, **40**:3439-3449.
16. Kremer M, Henn A, Kolb C, Basler M, Moebius J, Guillaume B, Leist M, Van den Eynde BJ, Groettrup M: **Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice.** *J Immunol* 2010, **185**:5549-5560.
17. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL: **Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.** *Cell* 1994, **78**:761-771.
18. Basler M, Groettrup M: **No essential role for tripeptidyl peptidase II for the processing of LCMV-derived T cell epitopes.** *Eur J Immunol* 2007, **37**:896-904.
19. Basler M, Lauer C, Beck U, Groettrup M: **The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.** *J Immunol* 2009, **183**:6145-6150.
20. de Verteuil D, Muratore-Schroeder TL, Granados DP, Fortier MH, Hardy MP, Bramouille A, Caron E, Vincent K, Mader S, Lemieux S *et al.*: **Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules.** *Mol Cell Proteomics* 2010, **9**:2034-2047.
21. Zaiss DM, de Graaf N, Sijts AJ: **The proteasome immunosubunit multicatalytic endopeptidase complex-like 1 is a T-cell-intrinsic factor influencing homeostatic expansion.** *Infect Immun* 2008, **76**:1207-1213.
22. Hutchinson S, Sims S, O'Hara G, Silk J, Gileadi U, Cerundolo V, Klenerman P: **A dominant role for the immunoproteasome in CD8+ T cell responses to murine cytomegalovirus.** *PLoS ONE* 2011, **6**:e14646.
23. Gileadi U, Moins-Teisserenc HT, Correa I, Booth BL, Dunbar PR, Sewell AK, Trowsdale J, Phillips RE, Cerundolo V: **Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein.** *J Immunol* 1999, **163**:6045-6052.
24. Sijts AJAM, Ruppert T, Reherrmann B, Schmidt M, Koszinowski U, Kloetzel PM: **Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes.** *J Exp Med* 2000, **191**:503-513.
25. Basler M, Lauer C, Moebius J, Weber R, Przybylski M, Kisselev AF, Tsu C, Groettrup M: **Why the structure but not the activity of the immunoproteasome subunit low molecular mass polypeptide 2 rescues antigen presentation.** *J Immunol* 2012, **189**:1868-1877.
- This publication describes a previously unrecognized function of immunoproteasome subunits in protecting CD8+ T cell epitope from the destruction by subunits of the constitutive proteasome.
26. Guillaume B, Chapiro J, Stroobant V, Colau D, Van Holle B, Parvizi G, Bousquet-Dubouch MP, Theate I, Parmentier N, Van den Eynde BJ: **Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.** *Proc Natl Acad Sci USA* 2010, **107**:18599-18604.
- This study describes the existence of intermediate proteasomes, which have different cleavage properties compared to the constitutive proteasome or the immunoproteasome.
27. Griffin TA, Nandi D, Cruz M, Fehling HJ, VanKaer L, Monaco JJ, Colbert RA: **Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits.** *J Exp Med* 1998, **187**:97-104.
28. Groettrup M, Standera S, Stohwasser R, Kloetzel PM: **The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome.** *Proc Natl Acad Sci USA* 1997, **94**:8970-8975.
29. De M, Jayarapu K, Elenich L, Monaco JJ, Colbert RA, Griffin TA: **Beta 2 subunit propeptides influence cooperative proteasome assembly.** *J Biol Chem* 2003, **278**:6153-6159.
30. Guillaume B, Stroobant V, Bousquet-Dubouch MP, Colau D, Chapiro J, Parmentier N, Dalet A, Van den Eynde BJ: **Analysis of the processing of seven human tumor antigens by intermediate proteasomes.** *J Immunol* 2012, **189**:3538-3547.
31. Kincaid EZ, Che JW, York I, Escobar H, Reyes-Vargas E, Delgado JC, Welsh RM, Karow ML, Murphy AJ, Valenzuela DM *et al.*: **Mice completely lacking immunoproteasomes show major changes in antigen presentation.** *Nat Immunol* 2012, **13**:129-135.
- In this paper the authors demonstrate, that mice completely lacking immunoproteasomes have major alterations in antigen presentation and stimulation of cytotoxic T cells.
32. Fehling HJ, Swat W, Laplace C, Kuehn R, Rajewsky K, Mueller U, von Boehmer H: **MHC class I expression in mice lacking proteasome subunit LMP-7.** *Science* 1994, **265**:1234-1237.
33. Nussbaum AK, Rodriguez-Carreno MP, Benning N, Botten J, Whitton JL: **Immunoproteasome-deficient mice mount largely normal CD8+ T cell responses to lymphocytic choriomeningitis virus infection and DNA vaccination.** *J Immunol* 2005, **175**:1153-1160.
34. Hayashi T, Faustman D: **NOD mice are defective in proteasome production and activation of NF-kappa B.** *Mol Cell Biol* 1999, **19**:8646-8659.
35. Hayashi T, Faustman D: **Essential role of human leukocyte antigen-encoded proteasome subunits in NF-kappa B activation and prevention of tumor necrosis factor-alpha-induced apoptosis.** *J Biol Chem* 2000, **275**:5238-5247.
36. Runnels HA, Watkins WA, Monaco JJ: **LMP2 expression and proteasome activity in NOD mice.** *Nat Med* 2000, **6**:1064-1065.
37. Kessler BM, Lennon-Dumenil AM, Shinohara ML, Lipes MA, Ploegh HL: **LMP2 expression and proteasome activity in NOD mice.** *Nat Med* 2000, **6**:1064.
38. Jang ER, Lee NR, Han S, Wu Y, Sharma LK, Carmony KC, Marks J, Lee DM, Ban JO, Wehenkel M *et al.*: **Revisiting the role of the immunoproteasome in the activation of the canonical NF-kappaB pathway.** *Mol Biosyst* 2012, **8**:2295-2302.
39. Pang KC, Sanders MT, Monaco JJ, Doherty PC, Turner SJ, Chen W: **Immunoproteasome subunit deficiencies impact differentially on two immunodominant influenza virus-specific CD8+ T cell responses.** *J Immunol* 2006, **177**:7680-7688.
40. Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ *et al.*: **Novel proteasome inhibitors have a beneficial effect in murine lupus via the dual inhibition of type I interferon and autoantibody secreting cells.** *Arthritis Rheum* 2012, **64**:493-503.
41. Nagayama Y, Nakahara M, Shimamura M, Horie I, Arima K, Abiru N: **Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice.** *Clin Exp Immunol* 2012, **168**:268-273.
42. Fitzpatrick LR, Khare V, Small JS, Koltun WA: **Dextran sulfate sodium-induced colitis is associated with enhanced low molecular mass polypeptide 2 (LMP2) expression and is attenuated in LMP2 knockout mice.** *Dig Dis Sci* 2006, **51**:1269-1276.
43. Schmidt N, Gonzalez E, Visekruna A, Kuhl AA, Loddenkemper C, Mollenkopf H, Kaufmann SH, Steinhoff U, Joeris T: **Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.** *Gut* 2010, **59**:896-906.
44. Frausto RF, Crocker SJ, Eam B, Whitmire JK, Whitton JL: **Myelin oligodendrocyte glycoprotein peptide-induced experimental allergic encephalomyelitis and T cell responses are unaffected by immunoproteasome deficiency.** *J Neuroimmunol* 2007, **192**:124-133.
45. Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schroter F, Prozorovski T, Lange N, Steffen J, Rieger M *et al.*: **Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress.** *Cell* 2010, **142**:613-624.

This study proposes that immunoproteasomes are more capable to degrade poly-ubiquitylated or oxidized proteins than constitutive proteasomes.

46. Opitz E, Koch A, Klingel K, Schmidt F, Prokop S, Rahnefeld A, Sauter M, Heppner FL, Volker U, Kandolf R *et al.*: **Impairment of immunoproteasome function by beta5i/LMP7 subunit deficiency results in severe enterovirus myocarditis.** *PLoS Pathog* 2011, **7**:e1002233.

47. Agarwal AK, Xing C, DeMartino GN, Mizrachi D, Hernandez MD, Sousa AB, Martinez de Villarreal AB, dos Santos HG, Garg A: **PSMB8 encoding the beta5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome.** *Am J Hum Genet* 2010, **87**:866-872.

48. Kitamura A, Maekawa Y, Uehara H, Izumi K, Kawachi I, Nishizawa M, Toyoshima Y, Takahashi H, Standley DM, Tanaka K *et al.*: **A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans.** *J Clin Invest* 2011, **121**:4150-4160.

This publication shows that a mutation in the LMP7 gene leads to autoinflammation in humans.

49. Arima K, Kinoshita A, Mishima H, Kanazawa N, Kaneko T, Mizushima T, Ichinose K, Nakamura H, Tsujino A, Kawakami A *et al.*: **Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome.** *Proc Natl Acad Sci USA* 2011, **108**:14914-14919.

The authors demonstrate that patients with Nakajo-Nishimura syndrome have a defect in proteasome assembly owing to a mutation in the LMP7 gene.

50. Zaiss DM, Bekker CP, Grone A, Lie BA, Sijts AJ: **Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases.** *J Immunol* 2011, **187**:2302-2309.

This paper shows that the immunoproteasome plays an important role in CD8<sup>+</sup> T cell mediated autoimmune diseases.

51. Groettrup M, Khan S, Schwarz K, Schmidtke G: **Interferon- $\gamma$  inducible exchanges of 20S proteasome active site subunits: Why?** *Biochimie* 2001, **83**:367-372.

52. Kalim KW, Basler M, Kirk CJ, Groettrup M: **Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation.** *J Immunol* 2012, **189**:4182-4193.

This study demonstrates that immunoproteasomes play a crucial role in T helper cell differentiation.

53. Hensley SE, Zanker D, Dolan BP, David A, Hickman HD, Embry AC, Skon CN, Grebe KM, Griffin TA, Chen W *et al.*: **Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses.** *J Immunol* 2010, **184**:4115-4122.

54. Rockwell CE, Monaco JJ, Qureshi N: **A critical role for the inducible proteasomal subunits LMP7 and MECL1 in cytokine production by activated murine splenocytes.** *Pharmacology* 2012, **89**:117-126.

55. Reis J, Hassan F, Guan XQ, Shen J, Monaco JJ, Papasian CJ, Qureshi AA, Van Way CW 3rd, Vogel SN, Morrison DC *et al.*: **The immunoproteasomes regulate LPS-induced TRIF/TRAM signaling pathway in murine macrophages.** *Cell Biochem Biophys* 2011, **60**:119-126.